A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
Top therapeutic areas (TAs) expected to drive biopharma market growth, 2022 to 2028
- Oncology: +$142B
- CNS (Neurology/Central nervous system): +$56B
- Endocrine: +$38B
- Immuno-modulators: +$36B
- Metabolic diseases: +$40B
- Cardiovascular: +$17B
- Blood: +$10B
- Musculo-skeletal: +$11B
- Other TAs: +$98B
- Anti-infectives: -$44B
Source: EY, How life sciences can make the right deals in a time of change, January 2024 - https://www.ey.com/en_gl/life-sciences/mergers-acquisitions-firepower-report